Lupus and T Cells

Cava, Antonio La

doi:10.1177/0961203308098191

Cited by 45 publications

(29 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…T lymphocytes act as an important part in all stages of the initiation, progression, and perpetration of the disease [12]. T cells from patients with SLE have been shown to be Systemic lupus erythematosus (SLE), induced by the interaction of susceptibility genes and environment risk factors, is a classical autoimmune diseases characterized by the dysregulation of innate and adaptive immune systems.…”

Section: Autophagy In Sle T Cellsmentioning

confidence: 99%

Update on the role of autophagy in systemic lupus erythematosus: A novel therapeutic target

Gao

Chen

Feng

et al. 2015

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Section: Autophagy In Sle T Cellsmentioning

confidence: 99%

Update on the role of autophagy in systemic lupus erythematosus: A novel therapeutic target

Gao

Chen

Feng

et al. 2015

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

“…Activation of anti-dsDNA-producing autoreactive B cells in lupus mice requires help from CD4+ helper T cells and overcoming of the suppression of CD4+CD25+ regulatory T cells. The activated CD4+ helper T cells produce elevated amounts of cytokines and help B cells to secrete autoantibodies that form immune complexes, which can bind to and/or remain trapped in tissue, with subsequent inflammation and organ damage [34]. Therefore, the elevation of CD4+CD25+ regulatory T cells can be a proper target to ameliorate lupus nephritis.…”

Section: Discussionmentioning

confidence: 99%

Bee Venom-Associated Th1/Th2 Immunoglobulin Class Switching Results in Immune Tolerance of NZB/W F1 Murine Lupus Nephritis

Lee

Lee²,

Kim³

et al. 2011

Am J Nephrol

View full text Add to dashboard Cite

Background/Aims: Bee venom (BV) therapy has been used to treat inflammatory diseases including rheumatoid arthritis in humans and in experimental animals. This study was conducted to examine the therapeutic effect of BV on established lupus nephritis in New Zealand Black/White (NZB/W) F1 female mice. Methods: Beginning at 18 weeks of age, mice were given a subcutaneous injection of either BV (3 mg/kg BW) or an equal volume of saline once a week until the end of the study. To examine the effect of BV on CD4+CD25+Foxp3+ regulatory T cells, splenocytes from NZB/W mice (23 weeks of age) were treated with BV (1 µg/ml) or PBS in the presence of anti-CD3Ε (1 µg/ml) and anti-CD28 antibodies (4 µg/ml) for 48 h. Results: BV administration delayed the development of proteinuria to a significant extent, prevented renal inflammation, reduced tubular damage, and reduced immune deposits in the glomeruli. Interestingly, CD4+CD25+ regulatory T cells were significantly increased in vitro and in vivo after BV treatment. Conclusion: Collectively, the administration of BV that has immune modulating effects represents an applicable treatment of lupus nephritis in NZB/W F1 mice.

show abstract

“…A defective regulation of Th1 and Th2 cytokines has been found typically in SLE and a Th1/Th2 imbalance appears to be an important factor responsible for the pathophysiology in lupus nephritis (Cava, 2009). The cytokine imbalance can thereby lead to alter immune responses which might influence the chemokines and subsequent severity of the disease.…”

Section: Discussionmentioning

confidence: 99%

“…The development of lupus and its manifestation involves several cell populations; however the T cells have been reported as a major contributor in the trigging and progression of disease (Cava, 2009). This heterogenous cell population proliferates differentially in response to antigen stimulation, secretes cytokines and triggers other cells to synthesize cytokines or chemokines (Kunz and Ibrahim, 2009), which are involved in the pathogenesis.…”

Section: Introductionmentioning

confidence: 99%

Interplay of Cytokines and Chemokines in the Pathogenesis of Systemic Lupus Erythematosus

Shah

Wanchu

Bhatnagar

2011

American Journal of Immunology

View full text Add to dashboard Cite

Problem statement: Dysbalance of T-helper-cell (Th) cytokines and chemokines was suggested to contribute to the pathogenesis of Systemic Lupus Erythematosus (SLE). Recent reports suggest the involvement of cytokines and chemokines in the pathogenesis of SLE, but their relationship with each other and particularly in the severity of disease, was not yet understood. We analyzed the interaction between cytokines and chemokines and their relationship with severity of disease in SLE. Approach: Serum levels of cytokines and chemokines were determined by ELISA and severity of disease were measured by by using SLE Disease Activity Index (SLEDAI) score. Results: The serum levels of cytokine (IL-2, IFN-γ, IL-6, IL-10 and IL-12) and chemokine (CCL2, CCL5 and CXCL10) were variably associated with disease activity in SLE patients. Strict interaction between cytokines and chemokines was observed in SLE patients. Interleukin-6 was positively correlated with CCL5 while IL-12 was also analogous correlated with CXCL10 in SLE patients. The kidney involvement in SLE patients was related with intense increased levels of cytokines (IFN-γ, IL-12) and chemokines (CCL2, CCL5 and CXCL10). Conclusion: These data suggest that interplay of cytokines and chemokines may be involved in the severity of disease. Also, a better understanding of the cytokines and chemokines interaction may likely to provide important clues to the pathogenic mechanism and pave the way toward more effective therapeutics.

show abstract

Lupus and T Cells

Cited by 45 publications

References 65 publications

Update on the role of autophagy in systemic lupus erythematosus: A novel therapeutic target

Update on the role of autophagy in systemic lupus erythematosus: A novel therapeutic target

Bee Venom-Associated Th1/Th2 Immunoglobulin Class Switching Results in Immune Tolerance of NZB/W F1 Murine Lupus Nephritis

Interplay of Cytokines and Chemokines in the Pathogenesis of Systemic Lupus Erythematosus

Contact Info

Product

Resources

About